Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
スポンサーリンク
概要
- 論文の詳細を見る
CS-622 is a prodrug type ACE inhibitor with a thiazepin ring. Its active form, CS-622 diacid, was slightly more potent than enalaprilat in inhibiting ACE isolated from rabbit lung. The inhibitory potency of CS-622 diacid on isolated rat aorta was 3 times that of enalaprilat. The inhibitory action of enalaprilat was abolished quickly by washing the aortic strip with drug-free solution, whereas that of CS-622 diacid was abolished only slowly. This difference suggests that CS-622 diacid binds to vascular ACE more firmly than enalaprilat. By oral administration, CS-622 was 3 times more potent than enalapril, and its onset of action was faster than that of enalapril, suggesting that the conversion of CS-622 to its active diacid occurs faster than the conversion of enalapril. Although CS-622 diacid was only slightly more potent than enalaprilat by intravenous administration, it had a longer duration than enalaprilat. Elimination of renal excretory function potentiated the action of captopril but not that of CS-622, suggesting that unlike captopril, only a small portion of CS-622 is excreted through the kidney.
- 公益社団法人 日本薬理学会の論文
著者
-
SADA Toshio
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
MIYAMOTO Masaaki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
KOIKE Hiroyuki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
OIZUMI Kiyoshi
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
NISHINO Hiroshi
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
NISHINO Hiroshi
Sankyo Research Laboratories, Sankyo Co., Ltd.
-
MATSUSHITA Youichi
Sankyo Research Laboratories, Sankyo Co., Ltd.
-
IIJIMA Yasuteru
Sankyo Research Laboratories, Sankyo Co., Ltd.
-
YANAGISAWA Hiroaki
Sankyo Research Laboratories, Sankyo Co., Ltd.
-
SADA Toshio
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
SADA Toshio
Sankyo Research Laboratories, Sankyo Co., Ltd.
-
KOIKE Hiroyuki
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
関連論文
- Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR.
- Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
- Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
- Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR.